| Symbol | SCYX |
|---|---|
| Name | SCYNEXIS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1 EVERTRUST PLAZA, JERSEY CITY, NJ 07302-6548 |
| Telephone | 201-884-5485 |
| Fax | — |
| — | |
| Website | https://www.scynexis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001178253 |
| Description | SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - SCYNEXIS INC <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001623632-26-000992 <b>Size:</b> 46 KB
Read moreSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNew Form SCHEDULE 13G/A - SCYNEXIS INC <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001649553-26-000059 <b>Size:</b> 12 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06954493 | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp | Phase1 | Vulvovaginal Candidiasis | Completed | 2023-07-12 | 2023-11-01 | ClinicalTrials.gov |
| NCT05668429 | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects | Phase1 | Fungal Disease | Completed | 2022-12-14 | 2023-01-28 | ClinicalTrials.gov |
| NCT05178862 | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasi… | Phase3 | Candidiasis, Invasive | Terminated | 2022-08-03 | 2025-12-16 | ClinicalTrials.gov |
| NCT05908682 | Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes | — | Vulvovaginal Candidiasis | Recruiting | 2022-07-28 | 2029-10-31 | ClinicalTrials.gov |
| NCT05399641 | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis | Phase3 | Vulvovaginal Candidiasis | Completed | 2022-05-01 | 2023-08-02 | ClinicalTrials.gov |
| NCT04307082 | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Phase1 | Fungal Infection | Completed | 2019-12-05 | 2020-06-30 | ClinicalTrials.gov |
| NCT04092751 | Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastati… | Phase1 | Pharmacokinetics | Completed | 2019-11-22 | 2019-12-20 | ClinicalTrials.gov |
| NCT04029116 | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recu… | Phase3 | Recurrent Vulvovaginal Candidiasis | Completed | 2019-10-21 | 2021-11-29 | ClinicalTrials.gov |
| NCT04092725 | Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subj… | Phase1 | Pharmacokinetics | Completed | 2019-09-09 | 2020-01-03 | ClinicalTrials.gov |
| NCT03987620 | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects Wit… | Phase3 | Candida Vulvovaginitis | Completed | 2019-06-07 | 2020-04-29 | ClinicalTrials.gov |
| NCT03672292 | Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Vori… | Phase2 | Invasive Pulmonary Aspergillosis | Terminated | 2019-01-22 | 2023-03-27 | ClinicalTrials.gov |
| NCT03734991 | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects Wit… | Phase3 | Candida Vulvovaginitis | Completed | 2019-01-04 | 2019-09-04 | ClinicalTrials.gov |
| NCT03363841 | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY… | Phase3 | Candidiasis, Invasive | Completed | 2017-11-15 | 2023-05-24 | ClinicalTrials.gov |
| NCT03253094 | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subje… | Phase2 | Candida Vulvovaginitis | Completed | 2017-08-01 | 2018-05-04 | ClinicalTrials.gov |
| NCT03059992 | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fun… | Phase3 | Invasive Candidiasis | Completed | 2017-04-01 | 2023-08-25 | ClinicalTrials.gov |
| NCT02679456 | Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Sub… | Phase2 | Vulvovaginal Candidiasis | Completed | 2015-11-01 | 2016-08-05 | ClinicalTrials.gov |
| NCT02244606 | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in t… | Phase2 | Mycoses | Completed | 2014-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01265511 | Study of SCY-635, Pegasys and Copegus in Hepatitis C | Phase2 | Hepatitis C Infection | Completed | 2010-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01290965 | Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients | Phase1 | Chronic Hepatitis C | Completed | 2007-04-01 | 2009-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Oral Placebo Tablets | Other | Phase PHASE2 | Invasive Pulmonary Aspergillosis | TERMINATED | NCT03672292 |
| Voriconazole | Other | Phase PHASE2 | Invasive Pulmonary Aspergillosis | TERMINATED | NCT03672292 |
| SCY-078 | Other | Phase PHASE2 | Invasive Pulmonary Aspergillosis | TERMINATED | NCT03672292 |
| SCY-635 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT01290965 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT01290965 |
| Copegus | Other | Phase PHASE2 | Hepatitis C Infection | COMPLETED | NCT01265511 |
| Pegasys | Other | Phase PHASE2 | Hepatitis C Infection | COMPLETED | NCT01265511 |
| SCY-635 | Other | Phase PHASE2 | Hepatitis C Infection | COMPLETED | NCT01265511 |
| Placebo | Other | Phase PHASE2 | Hepatitis C Infection | COMPLETED | NCT01265511 |
| Fluconazole | Other | Phase PHASE2 | Vulvovaginal Candidiasis | COMPLETED | NCT02679456 |
| SCY-078 | Other | Phase PHASE2 | Vulvovaginal Candidiasis | COMPLETED | NCT02679456 |
| [14C]-Ibrexafungerp | Other | Phase PHASE1 | Fungal Infection | COMPLETED | NCT04307082 |
| SCY-078 plus PRA | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092751 |
| PRA | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092751 |
| SCY-078 plus DAB | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092725 |
| DAB | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092725 |
| SCY-078 | Other | Phase PHASE2 | Candida Vulvovaginitis | COMPLETED | NCT03253094 |
| Fluconazole | Other | Phase PHASE2 | Candida Vulvovaginitis | COMPLETED | NCT03253094 |
| Placebo | Other | Phase PHASE3 | Candida Vulvovaginitis | COMPLETED | NCT03987620 |
| Ibrexafungerp | Other | Phase PHASE3 | Candida Vulvovaginitis | COMPLETED | NCT03987620 |
| Placebo | Other | Phase PHASE3 | Candida Vulvovaginitis | COMPLETED | NCT03734991 |
| Ibrexafungerp | Other | Phase PHASE3 | Candida Vulvovaginitis | COMPLETED | NCT03734991 |
| Placebo oral tablet | Other | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT04029116 |
| IBREXAFUNGERP | Other | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT04029116 |
| Fluconazole Tablet | Other | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT04029116 |
| Ibrexafungerp | Other | Phase PHASE1 | Fungal Disease | COMPLETED | NCT05668429 |
| Micafungin | Other | Phase PHASE2 | Mycoses | COMPLETED | NCT02244606 |
| Fluconazole | Other | Phase PHASE2 | Mycoses | COMPLETED | NCT02244606 |
| SCY-078 | Other | Phase PHASE2 | Mycoses | COMPLETED | NCT02244606 |
| SCY-078 | Other | Phase PHASE3 | Candidiasis, Invasive | COMPLETED | NCT03363841 |
| Ibrexafungerp | Other | Phase PHASE3 | Vulvovaginal Candidiasis | COMPLETED | NCT05399641 |
| Non-interventional study | Other | Preclinical | Vulvovaginal Candidiasis | RECRUITING | NCT05908682 |
| Ibrexafungerp | Other | Phase PHASE3 | Invasive Candidiasis | COMPLETED | NCT03059992 |
| Ibrexafungerp | Other | Phase PHASE1 | Vulvovaginal Candidiasis | COMPLETED | NCT06954493 |
| Echinocandin | Other | Phase PHASE3 | Candidiasis, Invasive | TERMINATED | NCT05178862 |
| Fluconazole | Other | Phase PHASE3 | Candidiasis, Invasive | TERMINATED | NCT05178862 |
| SCY-078 | Other | Phase PHASE3 | Candidiasis, Invasive | TERMINATED | NCT05178862 |
| Non-interventional study | OTHER | Preclinical | Vulvovaginal Candidiasis | RECRUITING | NCT05908682 |
| Echinocandin | DRUG | Phase PHASE3 | Candidiasis, Invasive | TERMINATED | NCT05178862 |
| [14C]-Ibrexafungerp | DRUG | Phase PHASE1 | Fungal Infection | COMPLETED | NCT04307082 |
| SCY-078 plus PRA | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092751 |
| PRA | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092751 |
| SCY-078 plus DAB | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092725 |
| DAB | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04092725 |
| Placebo oral tablet | DRUG | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT04029116 |
| IBREXAFUNGERP | DRUG | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT04029116 |
| Fluconazole Tablet | DRUG | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT04029116 |
| Oral Placebo Tablets | OTHER | Phase PHASE2 | Invasive Pulmonary Aspergillosis | TERMINATED | NCT03672292 |
| Voriconazole | DRUG | Phase PHASE2 | Invasive Pulmonary Aspergillosis | TERMINATED | NCT03672292 |
| Ibrexafungerp | DRUG | Phase PHASE1 | Vulvovaginal Candidiasis | COMPLETED | NCT06954493 |
| Micafungin | DRUG | Phase PHASE2 | Mycoses | COMPLETED | NCT02244606 |
| Fluconazole | DRUG | Phase PHASE3 | Candidiasis, Invasive | TERMINATED | NCT05178862 |
| SCY-078 | DRUG | Phase PHASE3 | Candidiasis, Invasive | TERMINATED | NCT05178862 |
| Copegus | DRUG | Phase PHASE2 | Hepatitis C Infection | COMPLETED | NCT01265511 |
| Pegasys | DRUG | Phase PHASE2 | Hepatitis C Infection | COMPLETED | NCT01265511 |
| SCY-635 | DRUG | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT01290965 |
| Placebo | DRUG | Phase PHASE3 | Candida Vulvovaginitis | COMPLETED | NCT03987620 |